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Background: Chronic kidney disease (CKD) and end stage renal disease (ESRD) are steadily increasing in prevalence
in the United States. While there is reasonable evidence that specific activities can be implemented by primary care
physicians (PCPs) to delay CKD progression and reduce mortality, CKD is under-recognized and undertreated in
primary care offices, and PCPs are generally not familiar with treatment guidelines. The current study addresses the
question of whether the facilitated TRANSLATE model compared to computer decision support (CDS) alone will
lead to improved evidence-based care for CKD in primary care offices.
Methods/Design: This protocol consists of a cluster randomized controlled trial (CRCT) followed by a process and
cost analysis. Only practices providing ambulatory primary care as their principal function, located in non-hospital
settings, employing at least one primary care physician, with a minimum of 2,000 patients seen in the prior year,
are eligible. The intervention will occur at the cluster level and consists of providing CKD-specific CDS versus
CKD-specific CDS plus practice facilitation for all elements of the TRANSLATE model. Patient-level data will be
collected from each participating practice to examine adherence to guideline-concordant care, progression of
CKD and all-cause mortality. Patients are considered to meet stage three CKD criteria if at least two consecutive
estimated glomerular filtration rate (eGFR) measurements at least three months apart fall below 60 ml/min. The
process evaluation (cluster level) will determine through qualitative methods the fidelity of the facilitated TRANS-
LATE program and find the challenges and enablers of the implementation process. The cost-effectiveness analysis
will compare the benefit of the intervention of CDS alone against the intervention of CDS plus TRANSLATE (practice
facilitation) in relationship to overall cost per quality adjusted years of life.
Discussion: This study has three major innovations. First, this study adapts the TRANSLATE method, proven
effective in diabetes care, to CKD. Second, we are creating a generalizable CDS specific to the Kidney Disease
Outcome Quality Initiative (KDOQI) guidelines for CKD. Additionally, this study will evaluate the effects of CDS
versus CDS with facilitation and answer key questions regarding the cost-effectiveness of a facilitated model for
improving CKD outcomes. The study is testing virtual facilitation and Academic detailing making the findings
generalizable to any area of the country.
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Chronic kidney disease (CKD) and end stage renal dis-
ease (ESRD) are steadily increasing in prevalence in the
United States (US) [1]. In 2000, there were 26 million
American adults with CKD, and this represented a 30%
increase over the past decade [1]. The annual incidence
of ESRD is projected to increase from its 2007 level of
111,000 to 143,000 by 2020, when the total US popula-
tion of people with ESRD is expected be over 770,000
[2,3]. The aging of the population and the rising preva-
lence of obesity, hypertension, and type 2 diabetes—the
major risk factors for CKD—contribute to this trend [4].
CKD is a serious condition; stage three CKD is associ-
ated with a five-year all-cause mortality rate of 24.3%
and a five-year need for renal replacement of 1.3%. Stage
four CKD is associated with a five-year 45.7% mortality
rate and a five-year 19.9% requirement for renal replace-
ment [5].
While there is reasonable evidence that specific activ-
ities can be implemented by primary care physicians
(PCPs) to delay CKD progression and reduce mortality
[6-12], CKD is under-recognized and undertreated in
primary care offices [13-15] and PCPs are generally not
familiar with treatment guidelines [13,14]. Even when di-
agnosed, CKD is a chronic condition that, like diabetes,
is frequently associated with co-morbidities, making ef-
fective treatment difficult due to the complexity of care.
The reasons for the slow rate of progress in improving
healthcare delivery, especially for chronic conditions
such as CKD, are complex. Rogers [16], in his classic
studies of diffusion of innovation, outlined several po-
tential barriers to adoption of innovation in many
industries. These included lack of time and monetary re-
sources, as well as organizational inefficiencies [16]. The
health sector has been notoriously slow to adopt new
approaches to care [17]. Competing demands and time
limitations often inhibit the ability of PCPs to adopt
evidence-based preventive services and manage chronic
diseases well [18,19], and it takes several years for
known evidence to become common practice [20-22].
The Chronic Care Model has been widely accepted
and utilized in primary care practices as a means of im-
proving evidence-based care [23,24]. Computer decision
support (CDS) tools generated through electronic med-
ical records and middleware vendors have been one im-
portant element of this model as a solution to some of
the problems of implementing evidence into practice.
However, a review by Garg et al. found that while CDS
improved physician behavior in 73% of the studies,
clinical markers were only improved 42% of the time
[25-31]. Peterson et al. developed a nine-point action
plan, including CDS and practice facilitation for imple-
menting the Chronic Care Model [32]. This plan is re-
ferred to as TRANSLATE. TRANSLATE stands for ‘setyour Target, use Registry and Reminder systems, get
Administrative buy-in, Network Information systems, Site
coordination, Local Physician Champion, Audit and feed-
back, Team approach, and Education’ [32]. The combined
efforts of the TRANSLATE model were highly effective in
improving diabetes care in a randomized control trial
(RCT) involving 24 practices and 8,405 diabetic patients
[32]. At 12 months, intervention practices had significantly
greater improvement in achieving recommended clinical
values for systolic blood pressure (SBP), Hemoglobin A1C
(HbA1C), and LDL cholesterol than control practices.
Control practices were provided with a report of their
process and outcome measures at baseline and were en-
couraged to continue usual quality improvement but did
not receive CDS at the point of care [32].
The current study addresses the question of whether
an adaptation of the facilitated TRANSLATE model with
CDS, compared to CDS alone, will lead to improved
evidence-based care for CKD in primary care offices,
thereby slowing the progression to ESRD and improving
patient health outcomes. A cluster randomized design
was chosen to minimize contamination across arms and
due to the logistical impossibilities of separating out
practice workflow by provider to provide CDS and/or
practice facilitation for only some providers within the
same medical practice.Specific aims
Specific aim 1
Conduct a cluster randomized controlled trial of point-of-
care CDS plus the full TRANSLATE model of practice
change, versus CDS alone in promoting evidence-based
care in primary care practices for all patients with an eGFR
<60 and >15 ml/min/1.73 m2 confirmed with repeat testing
over three or more months. (CKD stages three and four).Hypothesis 1.1
CDS practices using the TRANSLATE model will provide
a greater degree of evidence-based guideline-concordant
care for CKD than CDS-only practices.Specific aim 2
Conduct an intent-to-treat and process analysis between
the CDS practices with facilitation versus the CDS-only
practices of the clinical outcomes of CKD progression
and all-cause mortality.Hypothesis 2.1
Patients with stage three and four CKD in facilitated
practices will have slower CKD progression than patients
in CDS-only practices.
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Patients with stage three and four CKD in facilitated
practices will have significantly lower all-cause mortality
than stage three and four patients in CDS-only practices.
Hypothesis 2.3
The process evaluation will determine through qualita-
tive methods the fidelity of the facilitated TRANSLATE
program; find the challenges and enablers of the imple-
mentation process, and the contextual factors that con-
tribute to TRANSLATE decisions and strategies; and
translate lessons learned into pragmatic ‘best practices’
for future facilitation and dissemination.
Specific Aim 3
Conduct a cost-effectiveness analysis that will compare
the benefit of the intervention of CDS alone against the
intervention of CDS plus TRANSLATE (practice facilita-
tion) in relationship to overall cost per quality adjusted
years of life.
Hypothesis 3.1
The intervention of CDS plus TRANSLATE is more
cost-effective than the intervention of CDS alone.
Methods/design
This protocol consists of a cluster randomized controlled
trial (CRCT) followed by a process and cost analysis of the
study. The intervention consists of providing CKD-
specific CDS versus CKD-specific CDS plus practice facili-
tation [33] for all elements of the TRANSLATE model.
The study is being performed by the State University
of New York – University at Buffalo (UB) in collabor-
ation with the American Academy of Family Physicians
National Research Network (AAFP/NRN) with primary
care practices across the United States. Ethical approval
was obtained by the Institutional Review Boards at both
UB and AAFP/NRN for all aspects of the study.
Recruitment and randomization procedures
Inclusion criteria for clusters
Only practices providing ambulatory primary care as
their principal function, located in non-hospital settings,
employing at least one primary care physician, with a
minimum of 2,000 patients seen in the prior year, are
eligible. ‘Practices’ are defined as distinct office locations
that belong to organizations with one or more practice
sites. Candidate practices are drawn from members
of the Distributed Area Research and Therapeutics
(DARTNet) members. These members have point of
care decision support for preventive care and multiple
chronic diseases. CKD will be added to the chronic dis-
ease management reminder system.Inclusion criteria for patients
Patient-level data will be drawn from the population of
all active patients at each practice and will include all
patients diagnosed with stage three CKD. Patients are
considered to meet stage three CKD criteria if at least
two consecutive eGFR measurements at least three
months apart fall below 60 ml/min. At the inception of
the study, we used data from the preceding 12 months
to identify eligible patients (eGFR <60 and >15 ml/min)
with additional patients added to the analytical dataset
as they meet study criteria. These criteria were also used
to initiate the clinical decision support algorithms.
Recruitment
Recruitment for the study began in April 2012. The re-
cruitment goal is to enroll 36 practices total, randomized
into the two study arms. To date, 29 practices have been
enrolled in the study. 25 of these practices have been
randomized in two waves. The intervention period for
the first wave of 18 practices began in January of 2013.
The intervention for the second wave of seven practices
will begin in June of 2013. We plan to recruit and
randomize all additional practices by the end of 2013.
Consent was obtained at multiple levels; a practice ad-
ministrator signed a practice agreement and data use
agreement for each individual practice organization.
From each individual practice site (cluster), informed
consent was obtained from a site coordinator and a lead
physician at each site, as representatives of the cluster.
Consent was obtained prior to randomization.
Randomization protocol
In cases where two or more selected practices were drawn
from the same multi-practice organization, contamination
was limited by checking for clinician overlap. If overlap
was minimal, organization was used as a stratification vari-
able; if overlap was potentially problematic in terms of
contamination, practices were constrained to be in the
same group. From the pool of available practices, pre-
study information from electronic health record (EHR)
data on baseline performance characteristics related to
CKD or in general and variables which may influence out-
come measures, including practice and patient panel char-
acteristics as well as pre-study clinical measures were
collected (full-time equivalent physicians, mean HbA1c, %
diabetic, % stage four CKD, % of diabetics with HbA1c >9,
mean GFR, mean SBP, % with SBP >130, % with
SBP >140, % African American, % Hispanic, % uninsured)
[34]. Stratification variables included geographic region
and organization. All possible combinations of the 18 eli-
gible practices into two groups of nine were generated
[35] using the IML procedure in SAS [36], retaining order
so that the first designated group would be assigned
to the intervention, the remaining practices to controls
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stratification variables were retained (n = 1,728). For each
randomization, a balance criterion (defined as the sum of
squared differences on standardized variables between
control and intervention groups) was computed. After
examining the distribution of the balance criterion, a max-
imum allowable difference between the groups was
established and an optimal set of randomizations identi-
fied (n = 136). From this set, one was chosen using a ran-
dom number generator and practices were assigned to
treatment or control arms. This process was repeated for
the next group of seven practices, including a dummy
practice in the randomization procedure to accommodate
the uneven number of practices. The remaining practices
will be randomized using the same protocol. As with all
CRCTs, patients are not randomized per se; they are
assigned to treatment conditions along with the medical
practices in which they receive care.
Power analysis
Given the CKD national prevalence rate of 13% and an
expected average of 5,500 active patients per practice,
we expect roughly 715 CKD patients per practice (this
estimate is supported by a recent analysis of >110,000
individuals with stage three or four CKD drawn from
over 100 DARTNet practices.) With 18 practices per
arm and a minimum of 200 patients per practice
(smallest practice estimated at 2,000 patients with a con-
servative 10% prevalence of CKD over life of study) there
will be a minimum of 3,600 patients per arm (actual
expected sample size is over 14,000 per arm.) A sample
size of 3,600 per arm will provide >80% power to detect
a 0.18 effect size difference between two arms at a single
time point if the intra-class correlation (ICC) is 3%. This
effect size was assumed based on previous results from
the diabetes TRANSLATE study [32]. In terms of change
over time, a sample size of 3,600 will provide >80%
power to detect a small linear trend effect, increasing
from 0 at baseline to 0.2 standard deviation (SD) at final
follow up, with four observations per person and an ICC
of 3%, with a random effects structure with random
intercept and random slope [37].
Intervention design
Four elements of the TRANSLATE method will be
implemented in both groups, while the remaining ones
will apply to facilitated practices only. All interventions
will occur at the cluster level, and there will be no
randomization or specific intervention undertaken for
individual patients. The CDS-only practices will have
CKD decision support algorithms based on the Kidney
Disease Outcomes Quality Initiative (KDOQI guidelines
added to their existing CDS. There will be three separate
vendors that will be providing point of care support forthe study. Computer Integrated Networks of America
(CINA), Health Metrics Systems (HMS), and an EMR
with integrated CDS Medent. All practices will receive
one session of introductory academic detailing [38]
concerning the rationale for the algorithms. They will
also be provided related technical support on request.
Facilitated practices will receive the CKD-specific CDS,
as well as a practice facilitator to assist them in the im-
plementation of the full TRANSLATE model (Table 1).
Facilitation protocol
The facilitators' overall role is to help the practices im-
plement the TRANSLATE model to improve guideline-
concordant care for CDK. The facilitator will assist with
the site coordination, physician champion's needs, audit
and feedback, team approach, and education. Two prac-
tice facilitators are each assigned to half of the CDS+
facilitation practices. Throughout the course of the inter-
vention period, the facilitators will engage in virtual in-
teractions with the practices, in which they will work
with practice quality improvement (QI) teams to identify
and solve issues specifically related to their care of
patients with CKD and form and maintain relationships
with each practice. Facilitation objectives include: assis-
ting practices in setting goals to implement CKD
guidelines; helping practice teams, strategize, test, and
implement change; facilitating meetings and fostering a
continuous QI culture; serving as a liaison for data and
performance feedback; and sharing best practices and
linking intervention practices.
Due to the national scope of this project, facilitation
contacts will occur ‘virtually’ using videoconferencing
(GoToMeeting®), phone, and e-mail. General communi-
cation will entail a minimum of once monthly telecon-
ferences with each practice’s site coordinator to review
the status of the project, monthly virtual QI team meet-
ings, monthly calls between the academic mentors and
the lead physician, periodic learning collaboratives, and




From practice EHRs, we will collect the measurements
outlined in Table 2. Medication fulfillment data will be
collected from Surescripts RxHub through CINA or the
practice EHR. Death will be determined from informa-
tion in practice EHRs or from linkages to the National
Death Registry. We will check for deaths among patients
who have not made any visits in the prior 12 months in
the first two years of the intervention and in the prior
six months in the final year of the intervention. Medi-
care claims data will be obtained before and after the
intervention to allow for a proper cost analysis.
Table 1 Translate elements by intervention arm
TRANSLATE elements that will be used in both arms
Target: Common targets will be set for all practices and
tracked through the CKD tool. The CDS-only
practices will receive a quick reference guide for
the treatment of CKD
Registry and
reminder systems
CINA created a CKD registry and will maintain it
throughout the study period. Point-of-care decision
support specific to CKD will be provided to practice
staff and physicians prior to patient visits.
Administrative buy-in Obtain consent from each practice and all
practice sites asked to identify a physician
champion and site coordinator to oversee study
implementation at their site.
Network Information
systems
The information systems (EHRs and CDS)
will be used to create system level reports
across all practices.
TRANSLATE element that will be used only in facilitated CDS
practices
Site coordination A site coordinator at each practice will assemble
a quality improvement (QI) team that will meet
monthly to review performance data regarding
CKD. The site coordinator will also work with the
clinicians and practice staff to implement
workflow changes such as pre-visit planning,
standing orders, and patient education materials
to improve efficiency of disease management. In
addition, the site coordinator will be in contact
with the practice facilitator by videoconference
for assistance and advice.
Local physician
champion
This person will be the clinician leader and
educator for other providers in each practice.
Responsibilities will include supporting the site
coordinator and the QI team. This physician will
be in contact with the academic mentor for the
practice regarding clinical questions about CKD
and will participate in learning collaboratives with
the site coordinator.
Audit and feedback Practice, individual provider, and patient-level
outcome reports for the intervention practices
will be generated through CINA regarding the
seven performance measures (BP, HbAIC, LDL,
use of ACE/ARB, referral to a nephrologist,
smoking cessation and avoidance of NSAID or
Cox-2) and will be reviewed by the team.
Reports will also be reviewed quarterly with
the practice facilitator by videoconference. The
videoconference will allow the facilitator to
learn what worked in each practice and to
share what other practices have implemented
successfully.
Team approach A quality improvement (QI) team consisting of
the local physician champion, site coordinator
and nursing, front office, and administrative staff
will meet monthly to review progress of the CKD
project. Workflow changes will be recommended
and tested.
Education An educational program using academic
detailing and practice facilitation and
videoconferencing will be utilized to support
the practices’ efforts. All facilitated practices
will be assigned an academic practice mentor.
This mentor will be available to the office
physician champion and practice coordinator
to answer any questions and discuss plans.
Table 1 Translate elements by intervention arm
(Continued)
The academic mentor will review the
practice’s data and participate in a quarterly
videoconference with either the study
coordinator or the lead clinician to review
progress on the project.
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To determine the effectiveness of the TRANSLATE ele-
ments, it is crucial to first determine the degree of adop-
tion by the practice, and then systematically document
the challenges and enablers of the implementation
process, including the role of facilitation and the con-
textual factors that contribute to success. Qualitative
measures will be collected in tandem with the imple-
mentation of facilitated TRANSLATE elements to sup-
port real-time learning and a reiterative process of
evaluation (Table 3).
Semi-structured interviews will be conducted with the
physician champions at baseline and endpoint, askingTable 2 Clinical data elements
Data element Measure type
Year of birth Numerical
Gender M/F
Race/ethnicity Standard major groups and Other
Current smoking Current, never, past
Height and weight/BMI Hgt, wgt actual









25 OH Vitamin D Numerical result
Electrolytes Numerical result
Serum phosphorous Numerical result
PTH intact Numerical result
All medications Coded (NDC)/RxNorm
All diagnosis – active & inactive ICD-9
Blood pressure Systolic and diastolic
Estimated GFR Calculated value
Urine albumin/creatinine ratio Calculated value
Medicare insurance coverage Flag for medicare insurance
Nephrologists referrals Referral records (when available)
Table 3 Process evaluation activities
Process evaluation activities When collected Arm(s)
• Survey of practices' approaches to chronic care and practice change Baseline Endpoint Facilitated-CDS and CDS-only
• Semi-structured interviews with each Physician/ Clinician Champion. Baseline Endpoint Facilitated-CDS and CDS-only
o Interviews conducted with ALL Facilitated practices
o Interviews conducted with 9 CDS-only practices (4–5 from each round)
• Facilitator activity log on all interactions with the practice including: Ongoing Facilitated- CDS
o Emails
o Phone calls
o Monthly meetings with site coordinator
o QI team meetings
o Webinars/Conference calls
o Collaborative learning
o Interface/Meetings/consultations with the academic mentors
• Academic detailing activity log on interactions with the practice including: Weekly debrief with Facilitated- CDS
o Phone calls with physicians each academic mentor
o Emailsntd on their contacts with
o Webinars/Conference calls the practices
o Collaborative learning
o Interface/Meetings/consultations
• Site visits to 10 interventions and 10 comparator practices to observe workflow. Final 18 months of Facilitated-CDS and CDS-only
o Comparator practices selected at random. intervention
o Intervention practices selected using a dynamic multi-method approach (refer to
o site visit protocol)
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cesses in their office. Members of the evaluation team
will also conduct site visits at endpoint with both inter-
vention and comparator practices.
E-mail and other communication between practice
facilitators and the sites will be analyzed by the evalu-
ation team. Facilitators will also collect notes of meet-
ings, and practice activities; and submit this information
to the evaluation team on a regular basis.
Cost-effectiveness analysis
The hypothesis is that the intervention of CDS plus the
facilitated-TRANSLATE is more cost-effective than the
intervention of CDS alone, so the economic analysis will
focus on the TRANSLATE elements in delaying CKD
progression and reducing mortality due to CKD in the
practice settings of primary care physicians. Because
there is not a true control group (no clinic practice has
no intervention), the proposed project will examine the
relative costs of these interventions.
Three types of costs will be included into the total
costs of each intervention: the cost of providing services
in the clinic practices; the cost of treating CKD; and the
other healthcare expenses for patients. We plan to sur-
vey a sample of randomly selected practice clinics tomeasure the cost of providing CKD services. The investi-
gators have created and used a spreadsheet and guide-
line for collecting cost data from practices for previous
studies [39,40]. The practice facilitation activities of
TRANSLATE are expected to lead to more costs in the
intervention practices. The cost of training clinic practices
to use the CDS system and functions of TRANSLATE will
also be included into this type of cost, and the cost of
training (time) will be measured based on the hourly
wages of physician or medical staff. The cost of treating
CKD and other healthcare costs for patients will be based
on the claims data that we acquire from DARTNet.
Data analysis
Clinical data
The effectiveness measures will include the degree of
evidence-based guideline-concordant care for CKD pa-
tients (a patient-level score based on the percentage of
goals achieved); CKD progression for patients with stage
three and four CKD; and all-cause mortality rate.
Data analysis for hypothesis 1.1 (degree of evidence-based
care)
The primary outcome for this analysis will be a patient-
level score based on the percentage of goals achieved.
Fox et al. Implementation Science 2013, 8:88 Page 7 of 9
http://www.implementationscience.com/content/8/1/88Each goal will be assessed using EHR data for the previ-
ous year (or part of the year in which the patient is
eligible) at baseline, 12 months, 24 months, and 36
months. Secondary analyses will examine each outcome
individually using all available data and continuous mea-
sures (e.g., SBP, HbA1c, LDL) or dichotomous measures
(ACE/ARB, referral, smoking, NSAIDS). The structure
of the data is hierarchical (patients nested within prac-
tices) and longitudinal (repeated assessments on patients
at baseline, 12, 24, and 36 months).
Data analysis for hypothesis 2.1 (CKD progression)
The outcome for this analysis will be eGFR measurements
over time. There will be multiple eGFR measures per pa-
tient over the duration of the study. We will use general
linear mixed-effects models to estimate the rate of decline
in eGFR (random intercept, random slope) and the degree
to which the baseline covariates predict eGFR. Time for
each observation will be coded as days since baseline,
converted to months to aid interpretability. The primary
hypothesis of difference in slope between treatment
groups, adjusting for socio-demographic and clinical co-
variates, will be tested.
Data analysis for hypothesis 2.2 (all-cause mortality)
All-cause mortality will be confirmed using the National
Death Index to determine the exact date of death. The out-
come for the analysis will be time from baseline to death.
Patients who are alive at the end of the study period will be
censored at the end of the follow-up time. Assumptions of
the proportional hazards model will be checked for each
variable. Covariates will include baseline eGFR, defined as
the mean of the last two eGFRs prior to study entry, as well
as socio-demographic and clinical characteristics.
Process evaluation
Qualitative data for the process evaluation will be
analyzed using an immersion-crystallization approach
[41,42]. This content-driven approach allows the data to
speak for itself, as researchers immerse themselves in the
data repeatedly to identify themes that emerge [41].
Themes are identified around concepts that are expressed
repeatedly in the text and constantly compared back to
the data to ensure that they represent the data accurately.
Once themes are identified using this method, an add-
itional step in the analysis will be to compare the themes
with the elements of the TRANSLATE model to deter-
mine how well the data complement the interventional
model and how the data can illuminate the process of
practice adoption of each element.
Cost-effectiveness analysis
Analysis will compare the effectiveness-cost ratios be-
tween the two arms to examine which intervention ismore cost-effective. Because of the available claims data,
electronic medical records data, and mortality data from
the National Death Index, the analysis will calculate the
quality-adjusted life years (QALYs) lost due to CKD for
both interventions. The QALYs will be the most im-
portant effectiveness measure in the economic ana-
lysis, because QALYs can be valued as a dollar
amount. In the United States, $50,000 per QALY is a
decision rule that is often used to guide interpretation
of cost-effectiveness analyses. We will also do sensi-
tivity analysis by replacing this decision rule with
$25,000 or $100,000. We will compare the effective-
ness (dollar values of QALYs) with the cost, and de-
termine whether the effectiveness is larger than the
cost for each intervention. If the effectiveness is lar-
ger than the cost, these interventions will have cost
savings. If both interventions will produce cost sav-
ings, the proposed project will compare the cost sav-
ings for these two interventions and determine which
intervention has a high cost saving amount.
Trial status
Recruitment is ongoing. The first wave of practices was
recently randomized, and the official intervention period
began these practices in January of 2013. Initial baseline
data are being collected (Additional file 1). Data analysis
has not yet occurred. We anticipate that we will reach
full recruitment (36 practices) and all practices will have
entered the intervention (allowing a minimum of 18
months of intervention) by December of 2013. The trial
is registered as NCT01767883 on clinicaltrials.gov.
Discussion
Limitations
Some data elements like nephrology referral may be dif-
ficult to collect if they are entered as free text and not as
order entry. The practices will be worked with individu-
ally to try and overcome this. We may have difficulty
obtaining Medicare claims data in all practices, so we
may have to use a sample to complete this. Quality
of life measures may be difficult to obtain for cost-
effectiveness evaluation. This too, may have to be done
with a sub sample. We originally did not block rando-
mize within organizations, but two organizations were
found that were highly integrated in how they accom-
plished QI, so we had to change to block randomization
for the groups that had more integrated QI plans, other-
wise there would be cross contamination and a dilution
of a positive effect of facilitation.
Innovation and potential impact
This study has three major innovations. First, this study
adapts the TRANSLATE method, proven effective in
diabetes care [32], to CKD which, by definition, is a
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morbidities. Successful application of the TRANSLATE
model to complex disease conditions such as CKD will
demonstrate the viability of this model for aiding prac-
tices in practice transformation and in treatment of pa-
tients with other complex co-morbid conditions. Our
TRANSLATE framework also incorporates an imple-
mentation team that includes a clinician champion, site
coordinator, and an administrator to allocate resources
and guide and oversee implementation progress. It uti-
lizes information technology systems such as EMR or
middleware programs to produce registries to facilitate the
identification of high-risk patients and generate perform-
ance reports to provide data for ongoing feedback. In
future projects, this framework will be used to assess the
readiness of practices to participate in QI projects, and to
help diagnose why a project may be failing to improve out-
comes, thereby allowing for mid-course corrections.
Second, through this study we are creating a genera-
lizable CDS specific to the KDOQI guidelines for CKD: a
novel CDS application. The point-of-care CDS protocol
engine is integrated with multiple EHRs. The vendor ag-
nostic middleware tools we are using, consisting of CINA
and HMS, can be implemented against virtually any am-
bulatory EHR. The support algorithms have also been
adapted and implemented directly into the EHRs. It is
hoped that facilitated CDS and registry creation can be an
underlying system to rapidly improve evidence-based pre-
vention and chronic disease management with common
workflows regardless of condition.
Furthermore, this study will evaluate the effects of CDS
versus CDS with facilitation and answer key questions re-
garding the cost-effectiveness of a facilitated model for im-
proving CKD outcomes. In addition, the study is testing
virtual facilitation and Academic detailing making the
findings generalizable to any area of the country.
Finally, through the use of DARTNET, the study will
further a methodology for tracking in an efficient and
longitudinal manner a very large population over a long
period of time in real world practices, thereby allowing
both group level randomized CRCTs as well as popula-
tion-based economic analyses to be conducted from the
same study.Additional file
Additional file 1: Table S1. Consort 2010 checklist of information to
include when reporting a cluster randomised trial.
Abbreviations
CINA: Computer Integrated Networks of American; CKD: Chronic kidney
disease; CDS: Computer decision support; DARTNet: Distributed Area
Research and Therapeutics Network; EHR/ EMR: Electronic health record /
Electronic medical record; ESRD: End stage renal disease; HMS: Health MetricsSystems; KDOQI: National Kidney Foundation Kidney Disease Outcomes
Quality Initiative; PCP: Primary care physician; QALY: Quality adjusted years of
life; QI: Quality improvement.
Competing interests
The authors declare no potential conflicts of interest with respect to the
research, authorship, or publication of this article.
Authors’ contributions
CF is the principal investigator and responsible for the concept and design. BV
contributed to the design of the process evaluation and drafted the manuscript.
LK designed the process evaluation and reviewed the manuscript critically for
content. MD designed the randomization protocol and statistical analysis plan
and reviewed the manuscript critically for content. HF designed the cost-effecti-
veness analysis and reviewed the manuscript critically for content. WP contribu-
ted to the content and design of the study and reviewed the manuscript
critically for content. KK contributed to the design of the facilitation intervention
and the process evaluation and reviewed the manuscript critically for content.
JV contributed to the content and design of the study and reviewed the
manuscript critically for content. NL contributed to the overall protocol
development and standardization and reviewed the manuscript critically for
content. KP contributed to the concept and design of the study. All authors
read and approved the final manuscript.
Funding statement
This manuscript was supported by a grant from the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK090407.
Author details
1Department of Family Medicine, State University of New York – University at
Buffalo, 77 Goodell St, Buffalo, NY 14203, USA. 2Department of Family
Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
3Department of Health Systems, Management, and Policy, Colorado School
of Public Health, University of Colorado Denver, Denver, CO, USA. 4American
Academy of Family Physicians National Research Network, Leawood, USA.
5Department of Family Medicine, University of Kansas School of Medicine,
Kansas, USA. 6Division of Nephrology, Mount Sinai Medical Center, New York,
USA. 7National Kidney Foundation, New York, USA. 8Department of Family
Medicine and Community Health, University of Minnesota Medical School,
Minneapolis, Minnesota, USA.
Received: 23 May 2013 Accepted: 17 July 2013
Published: 8 August 2013
References
1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van-Lente F,
Levey AS: Prevalence of chronic kidney disease in the United States.
JAMA 2007, 298:2038–2047.
2. US Renal Data System: USRDS 2009 Annual Data Report: Atlas of Chronic
Kidney Disease and End-Stage Renal Disease in the United States. Bethesda,
MD: National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases; 2009.
3. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone
RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for
chronic kidney disease: evaluation, classification, and stratification.
Ann Intern Med 2003, 139:137–147.
4. Wetterhall SF, Olson DR, DeStefano F, Stevenson JM, Ford ES, German RR,
Will JC, Newman JM, Sepe SJ, Vinicor F: Trends in diabetes and diabetic
complications, 1980–1987. Diabetes Care 1992, 15:960–967.
5. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-
up and outcomes among a population with chronic kidney disease in a
large managed care organization. Arch Intern Med 2004, 164:659–663.
6. Khan S, Amedia CA Jr: Economic burden of chronic kidney disease. J Eval
Clin Pract 2008, 14:422–434.
7. Hostetter TH: Prevention of the development and progression of renal
disease. Am Soc Nephrol 2003, 14:S144.
8. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de-Jong PE, de-Zeeuw
D, Shahinfar S, Toto R, Levey AS: Progression of chronic kidney disease:
the role of blood pressure control, proteinuria, and angiotensin-conver-
ting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med
2003, 139:244–252.
Fox et al. Implementation Science 2013, 8:88 Page 9 of 9
http://www.implementationscience.com/content/8/1/889. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C,
Klarenbach S, Hemmelgarn BR: NSAID use and progression of chronic
kidney disease. Elsevier 2007, 120:280–280.
10. Weissman AJ, Ross PS, Nathan DM, Genuth S, Lachin J, Cefalu WT: Intensive
diabetes treatment and cardiovascular disease. Mass Med Soc 2006,
354:1751.
11. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van-Dijk DJ, Brenner BM:
Effects of blood pressure level on progression of diabetic nephropathy:
results from the RENAAL study. Am Med Assoc 2003, 163:1555.
12. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S,
Wilson DJ, Zuckerman A, Wenger NK, Investigators TNT, et al: Intensive lipid
lowering with atorvastatin in patients with coronary heart disease and
chronic kidney disease: the TNT (Treating to New Targets) study.
J Am Coll Cardiol 2008, 51:1448–1454.
13. Fox CH, Brooks A, Zayas LE, McClellan W, Murray B: Primary care
physicians’ knowledge and practice patterns in the treatment of chronic
kidney disease: an Upstate New York Practice-based Research Network
(UNYNET) study. J Am Board Fam Med 2006, 19:54–61.
14. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR: Identification and
referral of patients with progressive CKD: a national study. Am J Kidney
Dis 2006, 48:192–204.
15. Agrawal V, Ghosh AK, Barnes MA, McCullough PA: Awareness and knowledge
of clinical practice guidelines for CKD among internal medicine residents: a
national online survey. Elsevier Inc 2008, 52:1061–1069.
16. Rogers E: Diffusion of innovations. New York: Free Press; 1983.
17. Committee on Quality of Health Care in America IoM: Crossing the Quality
Chasm: A New Health System for the 21st Century. Washington DC: National
Academy Press; 2001.
18. Jaen CR, Stange KC, Nutting PA: Competing demands of primary care: a
model for the delivery of clinical preventive services. J Fam Pract 1994,
38:166–171.
19. Ostbye T, Yarnall KS, Krause KM, Pollak KI, Gradison M, Michener JL, Ostbye
T, Yarnall KSH, Krause KM, Pollak KI, et al: Is there time for management of
patients with chronic diseases in primary care? Ann Fam Med 2005,
3:209–214.
20. Oxman AD, Thomson MA, Davis DA, Haynes RB: No magic bullets - a
systematic review of 102 trials of interventions to improve professional
practice. Can Med Assoc J 1995, 153:1423–1431.
21. Berwick DM: A user’s manual for the IOM’s ‘quality chasm’ report.
Health Aff 2002, 21:80–90.
22. Lenfant C: Clinical research to clinical practice—lost in translation?
N Engl J Med 2003, 349:868–874.
23. Bodenheimer T, Wagner EH, Grumbach K: Improving primary care for
patients with chronic illness. JAMA 2002, 288:1775–1779.
24. Bodenheimer T, Wagner EH, Grumbach K: Improving primary care for
patients with chronic illness: the chronic care model, Part 2. JAMA 2002,
288:1909–1914.
25. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ,
Beyene J, Sam J, Haynes RB, Garg AX, Adhikari NKJ, et al: Effects of
computerized clinical decision support systems on practitioner
performance and patient outcomes: a systematic review. JAMA 2005,
293:1223–1238.
26. Cleveringa FG, Gorter KJ, van den-Donk M, Rutten GE, Cleveringa FGW,
Gorter KJ, van den-Donk M, Rutten GEHM: Combined task delegation,
computerized decision support, and feedback improve cardiovascular
risk for type 2 diabetic patients: a cluster randomized trial in primary
care. Diabetes Care 2008, 31:2273–2275.
27. Wells S, Furness S, Rafter N, Horn E, Whittaker R, Stewart A, Moodabe K,
Roseman P, Selak V, Bramley D, et al: Integrated electronic decision support
increases cardiovascular disease risk assessment four fold in routine
primary care practice. Eur J Cardiovasc Prev Rehabil 2008, 15:173–178.
28. Hicks LS, Sequist TD, Ayanian JZ, Shaykevich S, Fairchild DG, Orav EJ,
Bates DW, Hicks LS, Sequist TD, Ayanian JZ, et al: Impact of computerized
decision support on blood pressure management and control: a
randomized controlled trial. J Gen Intern Med 2008, 23:429–441.
29. Emery J, Morris H, Goodchild R, Fanshawe T, Prevost AT, Bobrow M, Kinmonth
AL, Emery J, Morris H, Goodchild R, et al: The GRAIDS Trial: a cluster randomised
controlled trial of computer decision support for the management of familial
cancer risk in primary care. Br J Cancer 2007, 97:486–493.
30. Fiks AG, Hunter KF, Localio AR, Grundmeier RW, Bryant-Stephens T, Luberti
AA, Bell LM, Alessandrini EA, Fiks AG, Hunter KF, et al: Impact of electronichealth record-based alerts on influenza vaccination for children with
asthma.[see comment]. Pediatrics 2009, 124:159–169.
31. Bryan C, Boren SA, Bryan C, Boren SA: The use and effectiveness of electronic
clinical decision support tools in the ambulatory/primary care setting: a
systematic review of the literature. Inform Prim Care 2008, 16:79–91.
32. Peterson KA, Radosevich DM, O’Connor PJ, Nyman JA, Prineas RJ, Smith SA,
Arneson TJ, Corbett VA, Weinhandl JC, Lange CJ, Hannan PJ: Improving
diabetes care in practice: findings from the TRANSLATE trial.
Diabetes Care 2008, 31:2238–2243.
33. Nagykaldi Z, Mold JW, Robinson A, Niebauer L, Ford A: Practice facilitators and
practice-based research networks. J Am Board Fam Med 2006, 19:506–510.
34. Glynn RJ, Brookhart MA, Stedman M, Avorn J, Solomon DH: Design of
cluster-randomized trials of quality improvement interventions aimed at
medical care providers. Med Care 2007, 45:S38–43.
35. Kraschnewski JL, Keyserling TC, Bangdiwala SI, Gizlice Z, Garcia BA, Johnston
LF, Gustafson A, Petrovic L, Glasgow RE, Samuel-Hodge CD: Optimized
probability sampling of study sites to improve generalizability in a
multisite intervention trial. Prev Chronic Dis 2010, 7:A10.
36. SAS (R) V 9.3 edition. Cary, NC: SAS Institute, Inc; 2011.
37. Hedeker D, Gibbons RD, Waternaux C: Sample size estimation for
longitudinal designs with attrition. Journal of Educational and Behaviorial
Statistics 1999, 24:70–93.
38. Soumerai SB, Avorn J: Principles of educational outreach (‘academic
detailing') to improve clinical decision making. Am Med Assoc 1990, 263:549.
39. Cohen DJ, Crabtree BF, Etz RS, Balasubramanian BA, Donahue KE, Leviton
LC, Clark EC, Isaacson NF, Stange KC, Green LW: Fidelity versus flexibility:
translating evidence-based research into practice. Am J Prev Med 2008,
35:S381–389.
40. Dodoo MS, Krist AH, Cifuentes M, Green LA: Start-up and incremental
practice expenses for behavior change interventions in primary care.
Am J Prev Med 2008, 35:S423–430.
41. Borkan J: Immersion/Crystallization. In Doing Qualitative Research Second
edition. Edited by Crabtree BF, Miller WL. Thousand Oaks: Sage Publications,
Inc; 1999:179–194.
42. Miller W, Crabtree B: Clinical research: a multimethod typology and
qualitative road map. In Doing qualitative research. 2nd edition. Edited by Miller
W, Crabtree B. Thousand Oaks, California: Sage Publications; 1999:179–194.
doi:10.1186/1748-5908-8-88
Cite this article as: Fox et al.: Improving evidence-based primary care
for chronic kidney disease: study protocol for a cluster randomized
control trial for translating evidence into practice (TRANSLATE CKD).
Implementation Science 2013 8:88.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
